Aging-Related Cancer Research and Drug Development

It is now widely established that cancer and aging are intrinsically linked. People over the age of 65 make up 60 percent of new cancer diagnoses and 70 percent of cancer deaths. As advances in medicine and healthcare maximize human life expectancy and the elderly population continues to grow, cancer rates are predicted to increase accordingly.

CD BioSciences offers preclinical contract research services dedicated to advancing the field of aging-related cancer research and drug development. With years of experience in the industry, our team of highly proficient biological scientists and experts is committed to providing comprehensive and reliable services to our clients.

Fig. 1 The aging-cancer cycle. (Singh R and Cuervo AM, 2012)

Our R&D Services by Type of Aging-Related Cancers

At CD BioSciences, we offer a wide range of research and development (R&D) services tailored to different types of aging-related cancers. By focusing on specific cancer types, we can provide specialized insights and solutions to address the unique challenges posed by each disease.

Breast cancer
Prostate cancer
Colorectal cancer
Lung cancer
Pancreatic cancer

Cancer Biology Services in Aging

At CD BioSciences, we employ technologies and methodologies to comprehensively analyze cancer biology in the context of aging-related cancers.

Genetic and epigenetic profiling. We perform comprehensive genetic and epigenetic profiling of aging-related tumors to identify key alterations that drive tumor initiation, progression, and metastasis. Through techniques such as next-generation sequencing, microarray analysis, and methylation profiling, we can unravel the genomic and epigenomic landscapes of aging-related cancers.
Tumor microenvironment analysis. In aging-related cancers, the tumor microenvironment undergoes dynamic changes that can influence tumor behavior and therapeutic response. At CD BioSciences, we employ advanced techniques to analyze the tumor microenvironment, including immune cell profiling, stromal cell characterization, and assessment of angiogenesis and hypoxia. Our analyses aid in understanding the complex interactions between tumor cells and their surrounding microenvironment, facilitating the development of targeted therapies.

Pathogenic Mechanism Analysis Services for Aging-Related Cancers

Unraveling the pathogenesis of aging-related cancers is essential for identifying key molecular pathways and cellular processes involved in tumor development. CD BioSciences offers comprehensive analysis services aimed at elucidating the pathogenesis of aging-related cancers, enabling the discovery of novel therapeutic targets.

Analysis of the interplay between aging and cancer risks. We help clients explore the complex interplay between aging processes and cancer risks. Our analysis services involve studying aging-related factors, such as chronic inflammation, hormonal changes, alterations in cellular metabolism, and epigenetic modifications, and their contribution to increased cancer susceptibility or altered cancer growth.
Analysis of the impact of accumulated cellular damage on cancer. We employ techniques such as comet assays, immunohistochemistry, and high-throughput sequencing to evaluate DNA damage levels in aging-related cancers. By examining DNA adducts, double-strand breaks, and chromosomal aberrations, we reveal the genotoxic stress experienced by tumor cells and its impact on cancer development.
Analysis of cellular senescence in cancer. We employ immunohistochemistry, flow cytometry, and gene expression profiling to identify and quantify senescence-associated biomarkers in cancer development. We offer analysis services to profile the senescence-related secretory phenotype (SASP) components using techniques like cytokine arrays, mass spectrometry, and RNA sequencing, to help clients study the impact of senescent cells on tumor microenvironment.
Analysis of immunosenescence in cancer. We utilize flow cytometry, immunohistochemistry, and gene expression analysis to profile immune cell populations in tumor tissues. By employing techniques like enzyme-linked immunosorbent assay (ELISA), multiplex immunoassays, and cytokine profiling arrays, we can evaluate the cytokine and chemokine profiles associated with immunosenescence in aging-related cancers.

Biomarker Identification Services for Aging-Related Cancers

CD BioSciences offers comprehensive biomarker identification services for aging-related cancers, allowing for the discovery and validation of novel biomarkers with clinical relevance. Using genomic sequencing, mass spectrometry, and immunoassays, we identify genomic and proteomic alterations that hold diagnostic or prognostic value for aging-related cancers. Our services aim to uncover specific biomarkers associated with aging-related cancer subtypes, treatment response, and disease progression.

Disease Model Customization Services for Aging-Related Cancers

CD BioSciences provides disease model customization services to facilitate robust and reliable preclinical research. We offer in vitro and in vivo model customization services, such as the patient-derived xenograft (PDX) model, cell-based models, and animal models, to help clients explore the molecular mechanisms underlying tumor development, progression, and response to interventions. Our disease models play a crucial role in evaluating different pharmacological interventions.

Drug Discovery and Development Services for Aging-Related Cancers

CD BioSciences offers comprehensive drug discovery and development services specifically tailored for aging-related cancers. Our services encompass various stages of the drug development process, from target identification and validation to preclinical studies. We conduct rigorous in vitro and in vivo studies to assess the efficacy of potential drug candidates against aging-related cancers. We perform comprehensive pharmacokinetic and toxicity studies to assess the safety and tolerability of potential drug candidates. These studies provide valuable data on compound absorption, distribution, metabolism, excretion (ADME) as well as potential adverse effects.

CD BioSciences is dedicated to advancing aging-related cancer research and drug development through our comprehensive range of services. Our extensive expertise and commitment to scientific excellence make us an ideal partner for accelerating the development of novel therapies for aging-related cancers. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

Sedrak MS, Cohen HJ. The Aging-Cancer Cycle: Mechanisms and Opportunities for Intervention. J Gerontol A Biol Sci Med Sci, 2023, 78 (7): 1234-1238.
Zinger A, et al. Cancer and Aging - the Inflammatory Connection. Aging Dis, 2017, 8 (5): 611-627.